Final guidance on use of axitinib for treating kidney cancer and sipuleucel-T for prostate cancer. Guidance issued to the NHS today, recommends that the drug axitinib, known as Inlyta by Pfizer, should be available as a second line treatment for kidney cancer. A separate new guide did not recommended sipuleucel-T, known as Provenge, for treating…
